These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29765222)

  • 1. Improving adherence to gout therapy: an expert review.
    Perez-Ruiz F; Desideri G
    Ther Clin Risk Manag; 2018; 14():793-802. PubMed ID: 29765222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better outcomes for patients with gout.
    Day R; Nguyen A; Graham G; Aung E; Coleshill M; Stocker S
    Inflammopharmacology; 2020 Oct; 28(5):1395-1400. PubMed ID: 32095979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment approaches and adherence to urate-lowering therapy for patients with gout.
    Aung T; Myung G; FitzGerald JD
    Patient Prefer Adherence; 2017; 11():795-800. PubMed ID: 28458524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming adherence issues and other barriers to optimal care in gout.
    Nasser-Ghodsi N; Harrold LR
    Curr Opin Rheumatol; 2015 Mar; 27(2):134-8. PubMed ID: 25633242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication adherence among patients with gout: A systematic review and meta-analysis.
    Scheepers LEJM; van Onna M; Stehouwer CDA; Singh JA; Arts ICW; Boonen A
    Semin Arthritis Rheum; 2018 Apr; 47(5):689-702. PubMed ID: 29198878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study.
    Abhishek A; Jenkins W; La-Crette J; Fernandes G; Doherty M
    Rheumatology (Oxford); 2017 Apr; 56(4):529-533. PubMed ID: 28082620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting.
    Lee S; So MW
    Mod Rheumatol; 2016 Nov; 26(6):950-955. PubMed ID: 27142782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional internet-based patient survey of the management strategies for gout.
    Singh JA; Shah N; Edwards NL
    BMC Complement Altern Med; 2016 Mar; 16():90. PubMed ID: 26931313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.
    Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KD; Portek I; WIlliams KM; Westbrook JI
    BMJ Open; 2017 Oct; 7(10):e017281. PubMed ID: 29042386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout.
    Te Kampe R; Boonen A; Jansen TL; Elling JM; Flendrie M; van Eijk-Hustings Y; Janssen M; van Durme C; de Vries H
    BMC Med Inform Decis Mak; 2022 Apr; 22(1):95. PubMed ID: 35392890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casebook consults: improving outcomes in gout (multimedia activity).
    Doghramji PP; Mandell BF; Pope RS
    Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with initiation and persistence of urate-lowering therapy.
    Dehlin M; Ekström EH; Petzold M; Strömberg U; Telg G; Jacobsson LT
    Arthritis Res Ther; 2017 Jan; 19(1):6. PubMed ID: 28095891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis.
    Yin R; Li L; Zhang G; Cui Y; Zhang L; Zhang Q; Fu T; Cao H; Li L; Gu Z
    BMJ Open; 2018 Apr; 8(4):e017542. PubMed ID: 29643150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing medication adherence in patients with gout: A descriptive correlational study.
    Chua XHJ; Lim S; Lim FP; Lim YNA; He HG; Teng GG
    J Clin Nurs; 2018 Jan; 27(1-2):e213-e222. PubMed ID: 28618105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term adherence and persistence with febuxostat among male patients with gout in a routine clinical setting.
    Lee S; So MW; Ahn E
    Mod Rheumatol; 2019 Jul; 29(4):662-668. PubMed ID: 29856667
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.